Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced that the European Commission has granted marketing authorization to Bydureon (exenatide 2 mg powder and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results